Thermo Fisher Scientific CD262 (DR5) Monoclonal Antibody (MD5-1), PE, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

0.25 µg/test

View 10 publications 10 publications

Product Specifications

Species Reactivity

Mouse

Published species

Mouse

Host/Isotype

Armenian hamster / IgG

Recommended Isotype Control

Armenian Hamster IgG Isotype Control (eBio299Arm), PE, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

MD5-1

Conjugate

PE PE PE

View additional formats

• Biotin
• Functional Grade
• Request custom conjugation

Excitation/Emission Max

565/576 nm View spectra

Form

Liquid

Concentration

0.2 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_465999

Product Specific Information

Description: The MD5-1 monoclonal antibody reacts with mouse DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 mRNA is expressed broadly by normal tissue and human antigen is also expressed by some tumor cell lines.

Applications Reported: The MD5-1 antibody has been reported for use in flow cytometric analysis.

Applications Tested: The MD5-1 antibody has been tested by flow cytometric analysis of mouse DR5-transfected cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.